000025725 000__ 02901cam\a2200517\i\4500
000025725 001__ 25725
000025725 003__ SzGeWIPO
000025725 005__ 20230210125008.0
000025725 008__ 071115s2009    ne |||||r|||| 00| 0 eng d
000025725 035__ $$a(wipo)0
000025725 035__ $$a(OCoLC)1159564724
000025725 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000025725 041__ $$aeng
000025725 050_4 $$aK10$$b.O9
000025725 08204 $$a343.08705$$219
000025725 084__ $$a27$$qGB
000025725 1001_ $$aMitchell, Andrew D.,$$aVoon, Tania.
000025725 24510 $$aPatents and Public Health in the WTO, FTAs and Beyond :$$bTension and Conflict in International law.
000025725 264_1 $$aThe Hague [The Netherlands] :$$bKluwer Law International,$$c2009.
000025725 300__ $$a1 volume ([31] pages) ;$$c[28] cm.
000025725 336__ $$atext$$btxt$$2rdacontent
000025725 337__ $$aunmediated$$bn$$2rdamedia
000025725 338__ $$avolume$$bnc$$2rdacarrier
000025725 4901_ $$aJournal Of World Trade,$$x1011-6702 ;$$vJune 2009, Vol 43, No 3, pages 571-601
000025725 520__ $$aBy mandating patent protection for pharmaceutical products, the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement) of the World Trade Organization (WTO) creates difficulties for developing countries seeking to import medicines to deal with serious public health concerns. In 2001, WTO Members began working towards a solution to this problem. Their work led to a temporary waiver of certain TRIPS obligations and a proposal for a formal amendment of the TRIPS Agreement. However, the waiver remains underutilized and the amendment still lacks the necessary support of WTO Members for it to come into effect, suggesting that Members need to re-evaluate their commitment to affordable medicines while testing the workability of the waiver before making it permanent. Moreover, the potential of bilateral approaches to the problem of access to medicines for developing countries in the context of international trade is not being realized. On the contrary, preferential trade agreements concluded with the United States (US), in particular, are extending patent protection and diminishing flexibilities available under the TRIPS Agreement to address public health concerns. A pattern of contradictions exists between the WTO rhetoric on the one hand and Members’ domestic frameworks, bilateral agreements, and unilateral actions on the other. When it comes to attaining a coherent approach under international law towards reconciling patents and public health, the outlook is bleak.
000025725 650_0 $$aPublic health.
000025725 650_0 $$aInternational trade.
000025725 650_0 $$aForeign trade regulation.
000025725 650_0 $$aInternational economic relations.
000025725 650_0 $$aCommercial law$$xPeriodicals.
000025725 650_0 $$aPatents.
000025725 650_4 $$aPublic health
000025725 650_4 $$aTRIPS
000025725 650_4 $$aPatents
000025725 650_4 $$aAccess to medicine
000025725 650_6 $$aDroit commercial$$xPériodiques.
000025725 650_6 $$aCommerce exterieur$$xRéglementation$$xPériodiques.
000025725 650_6 $$aCommerce extérieur$$vPériodiques$$xRéglementation.
000025725 650_6 $$aCommerce international.
000025725 903__ $$aJournal Of World Trade ;$$vJune 2009, Vol 43, No 3, pages 571-601.
000025725 904_a $$aArticle
000025725 942__ $$cART$$2ddc
000025725 952__ $$w2010-04-01$$p2010-0302$$u39797$$bMAIN$$10$$kGB 27$$v2010-04-01$$zLibrary$$71$$cLibrary
000025725 980__ $$aBIB
000025725 999__ $$c28091$$d28091